HROW Stock Forecast & Price Target

Harrow is a US-based ophthalmology company that is expected to experience continued financial success and growth. This is primarily driven by their current assets and differentiated product in the dry-eye market, as well as their expansion through acquisitions and internal development. Their strong management team and recent launch of a new biosimilar product also indicate potential for future revenue growth. The company has a target of reaching $250 million in quarterly revenue by 2027 and is utilizing innovative tools such as AI to target top customers and mitigate risks in the industry through DCF valuation.

Harrow is a profitable biotechnology company that has slowly built a strong presence in the eyecare space by establishing relationships with a majority of eyecare professionals and acquiring FDA-approved therapeutics. While the company's focus on specialty eyecare products may provide a competitive advantage, the risk of losing ASC pass-through status for IHEEZO and DEXYCU, as well as potential pricing challenges, could negatively impact future revenue and earnings growth. The company's lack of significant M&A activity in its model also presents a risk, as larger deals could potentially change its cash flow and leverage trajectory. Additionally, the success of the company's biosimilar products and its dropless strategy will play a critical role in driving future revenue growth.